Salute e Benessere
SKAN, the Wellcome Sanger Institute and University of Newcastle to study early stem cell mutations in rare blood disorder
Researchers will work with leading LCH treating research centres worldwide to cover LCH driven by different genetic mutations with SKAN specifically creating a large cohort of Indian children for the study. The study comes at a time when researchers are still grappling with understanding how some genetic mutations that drive LCH result in lesions appearing in different parts of the body at different times. Researchers hope that the study will pave the way for better understanding the disease's progression and possible early interventionist strategies for its management.
said
, said,
Newcastle University and its Principal Investigator, Prof. Matthew Collin , who have played a major role in establishing diagnostic and blood monitoring pipelines for LCH, (now adopted by the UK NHS Genomic Medicine Services), will also be part of this collaboration.
said,
said,
SKAN is a Bengaluru-based not-for-profit medical research trust that leverages transformational technologies to develop new therapies for ageing and neurological ailments, cardiovascular diseases, diabetes remission and lifestyle related disorders. SKAN applies its expertise in gut microbiome, genomics, stem cells, molecular biology, biomarkers, immunotherapies, nutrition, and alternate therapies to uncover kinder and gentler treatment protocols for ailments. Bioinformatics at SKAN vigorously pursues cutting edge artificial intelligence, machine learning and other advanced technologies to predict, pre-empt, diagnose, treat, and facilitate remission of medical disorders. The Mission statement of SKAN is " ".
Media contact: contactus@skanrt.in
Careers: Talent@SKANrt.in
Founded to sequence the human genome, the Sanger Institute is a biomedical research centre recognized globally for undertaking large scale genome science that forms the foundations of knowledge in biology and medicine. In order to deliver on its mission to "apply and explore genomic technologies at scale to advance the understanding of biology and improve health", the Sanger Institute is committed to collaborating, leading, convening, engaging globally and providing world-class training to scientists and specialists in genomic research. The Sanger Institute strategically deploys its Wellcome core funding to enable faculty-driven genomic science, making discoveries not easily made elsewhere.
As a member of the Russell Group, an association of 24 research-intensive institutions in the UK, Newcastle is delivering . From reversing Type 2 diabetes to protecting cultural property, Newcastle researchers are tackling international challenges to improve lives and influence policy around the world. Newcastle has
Photo: https://mma.prnewswire.com/media/2447397/SKAN_theWellcomeSangerInstitute_UniversityofNewcastle.jpg
Logo: https://mma.prnewswire.com/media/2082007/4257624/SKAN_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/skan-the-wellcome-sanger-institute-and-university-of-newcastle-to-study-early-stem-cell-mutations-in-rare-blood-disorder-302181490.html